Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial.
Adjunctive sublingual isosorbide dinitrate improves successful voiding trial after catheter removal
Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial.
To evaluate the synergistic effect and safety of sublingual isosorbide dinitrate (isosorbide dinitrate) to facilitate successful voiding trial after catheterization for acute urinary retention (acute urinary retention) secondary to benign prostatic hyperplasia (benign prostatic hyperplasia).
Were randomly assigned to receive either standard therapy (α1-blocker and 5α-reductase inhibitor) alone ( n = 40) or in combination with daily sublingual isosorbide dinitrate 10 mg for 21 days ( n = 40).
success doubled with isosorbide, from about 1 in 4 to 1 in 2
Post-void residual volume decreased significantly after treatment in both groups (within-group p < 0.001), with a greater overall reduction observed in the isosorbide dinitrate group ( p = 0.002).
Prostate-specific antigen levels remained stable, with no significant within- or between-group differences.
On multivariable logistic regression analysis, adjunctive isosorbide dinitrate therapy independently predicted successful trial without catheter (adjusted OR 3.27, 95% CI 1.23-8.70; p = 0.017).
No serious adverse events were observed.
Adjunctive sublingual isosorbide dinitrate significantly improves urinary outcomes following acute urinary retention and reduces residual urine volume without increasing adverse events.
This combination therapy offers a safe and effective strategy to improve the success of trial without catheter in patients with benign prostatic hyperplasia-related acute urinary retention.